Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).

Hutson, Thomas E.; Procopio, Giuseppe; Escudier, Bernard; Negrier, S.; Knox, J. J.; Keilholz, Ulrich; Szczylik, Cezary; Brueckner, Andreas; Kalmus, J.; Bokemeyer, C.

doi:10.1200/jco.2010.28.15_suppl.4614

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the wider usage in clinical practice, side-effects of sorafenib began to be recognized and some of which may be potentially life threatening, such as congestive heart failure (CHF), arterial thrombosis, wound dehiscence, haemorrhage, hypertension, and renal dysfunction (Chu et al, 2008;Wu et al, 2008;Chu et al, 2009;Je et al, 2009;Kerkela et al, 2009;Choueiri et al, 2010;Ewer et al, 2010;Hutson et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer

Zhang

Zhang²,

Yu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Fatal adverse events (FAEs) have been reported with sorafenib, a vascular endothelial growth factor receptor kinase inhibitor (VEGFR TKI). We here performed an up-to-date and detailed meta-analysis to determine the overall risk of FAEs associated with sorafenib. Methods: Databases, including PubMed, Embase and Web of Science, and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies. Eligible studies included randomized controlled trials evaluating sorafenib effects in patients with all malignancies. Summary incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated for FAEs. In addition, subgroup analyses were performed according to tumor type and therapy regimen. Results: 13 trials recruiting 5,546 patients were included in our analysis.

show abstract